Anti-CD27 antibodies and uses thereof

US12110337B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Li-Sheng Lu · Mountain View, US
• Mark J. Selby · San Francisco, US
• Alan J. Korman · Piedmont, US
• Shrikant Deshpande · Fremont, US
• Mohan Srinivasan · Cupertino, US
• Jun Zhang · Xiamen, CN
• Haichun Huang · Fremont, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Ekaterina Deyanova · Lawrenceville, US

Key dates

• Filing date: Apr 3, 2019
• Grant date: Oct 8, 2024
• Expiry date: Jul 2, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.